Bacil Pharma Ltd
- Market Cap ₹ 17.6 Cr.
- Current Price ₹ 12.3
- High / Low ₹ 61.8 / 11.0
- Stock P/E 27.2
- Book Value ₹ 17.3
- Dividend Yield 0.00 %
- ROCE 3.93 %
- ROE 6.21 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.71 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.21% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.25 | 0.14 | |
| Operating Profit | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 | -0.14 |
| OPM % | |||||||||||||
| 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.24 | 0.31 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 0.99 | 0.17 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -57.58% | ||
| -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.56 | 0.65 | |
| EPS in Rs | -0.05 | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.09 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 77% |
| 3 Years: | 131% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 13% |
| 3 Years: | 14% |
| 1 Year: | -67% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 3% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 | 10.84 |
| 0.14 | 0.27 | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 | 0.00 | |
| 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 | |
| Total Liabilities | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| CWIP | 5.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 | |
| Total Assets | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.06 | 0.00 | 1.44 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 | |
| -0.33 | -0.05 | 0.02 | -1.20 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 | |
| Net Cash Flow | -0.07 | 0.01 | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.20 | 0.01 | 2.82 | -2.29 |
| Free Cash Flow | 0.24 | -3.21 | 0.00 | 1.14 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| CFO/OP | -236% | -46% | 0% | -497% | 115% | 211% | 250% | 2,506% | 88% | 0% | -160% | -284% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% | 3.93% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Loans and Advances given (Non-Current) INR Lakhs |
|
|||||||||
| Total Investments Held (Non-Current + Current) INR Lakhs |
||||||||||
| Number of Permanent Employees count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th August 2026
- Board meeting scheduled for 25 August 2026 to discuss appointment of directors.
- Un-Audited Financial Results For The Quarter Ended 30Th June, 2026
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August, 2026
- Bacil Pharma approved Q1 FY27 unaudited results on 12 August 2026; profit was ₹30.12 lakh.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 12Th August 2026
- Board meeting on 12 August 2026 to approve unaudited results for quarter ended 30 June 2026.
-
Announcement Under Regulation 30, LODR
- Bacil Pharma incorporated wholly owned subsidiary Bacil Research & Development Private Limited on 28 July 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Operational Status:[1]
Company is non operational for the past many years. It has not carried out any major business activity and management is considering diversifying their business activities and have deployed surplus funds as temporary loans and advances